Results from a phase II study, led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy, BC Cancer, and the Canadian Cancer trials Group, suggest that circulating tumor DNA analyses could be used as an early marker of immunotherapy response in advanced non-small cell lung cancer patients and may help guide therapy.
A research team at UVA Health is testing the ability of focused ultrasound to increase the immune response to immunotherapy in melanoma. UVA’s work with focused ultrasound already has led to life-changing new treatments for Parkinson’s disease and essential tremor and pushed the technology to the forefront of medical research.
